ArriVent Biopharma Funding: $150M Raised, Series A
ArriVent Biopharma has raised $150M in total funding. Latest round: Series A. Backed by Hillhouse Capital Group, Boyu/Zoo Capital, OrbiMed.
ArriVent Biopharma funding overview
ArriVent Biopharma has raised $150M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series A. Investors on record include Hillhouse Capital Group, Boyu/Zoo Capital, OrbiMed, Octagon Capital Advisors, Lyra Capital, Lilly Asia Ventures. 6 distinct backers are named across the disclosed rounds.
ArriVent Biopharma at a glance
Total raised
$150M
Latest round
Series A
Notable investors
Hillhouse Capital Group, Boyu/Zoo Capital, OrbiMed, Octagon Capital Advisors, Lyra Capital, Lilly Asia Ventures
Frequently asked about ArriVent Biopharma funding
How much has ArriVent Biopharma raised?
ArriVent Biopharma has raised $150M in total disclosed funding across the rounds on record.
Who has invested in ArriVent Biopharma?
Hillhouse Capital Group, Boyu/Zoo Capital, OrbiMed, Octagon Capital Advisors, Lyra Capital, Lilly Asia Ventures are named among the investors backing ArriVent Biopharma.
What was the latest ArriVent Biopharma funding round?
The most recent disclosed round is a Series A.
Where is ArriVent Biopharma based?
No headquarters location is disclosed for ArriVent Biopharma.
Every ArriVent Biopharma figure above comes from filings and announced rounds in the StartupFundraising company database and is revised as new rounds are recorded. The lists below compare companies at a similar stage.
